DUBAI, Sept. 26, 2025 /PRNewswire/ — Pony.ai, a global leader in autonomous driving technology, today announced that it has been granted permit by Dubai‘s Roads and Transport Authority (RTA) to conduct autonomous driving trials on the emirate’s roads. This milestone follows the company’s partnership with Dubai‘s RTA, unveiled earlier this year, and marks a major step toward commercial deployment in the Middle East region.

The announcement comes on the heels of the Dubai World Congress for Self-Driving Transport 2025, which concluded on September 25 at the Dubai World Trade Centre. As an honorable partner of the event, Pony.ai showcased its cutting-edge autonomous driving technologies and a robotaxi model slated for deployment in Dubai.

Held under the theme “Redefining Mobility: The Path to Autonomy”, this year’s Congress highlighted Dubai‘s vision to transform 25% of urban trips to be smart and autonomous by 2030. The event brings together policymakers, global industry leaders and innovators to accelerate the adoption of self-driving technologies.

Pony.ai’s showcase received a warm welcome from conference guests. Government representatives, industry experts, and potential partners showed strong interest in Pony.ai’s full-stack self-driving technology and its planned deployment in Dubai. The interactive booth facilitated in-depth technical exchanges and demonstrated Pony.ai’s commitment to safe and scalable autonomous mobility solutions.

With the new testing permit, Pony.ai has begun pilot testing in certain areas. The service is scheduled to be launched commercially without a driver in 2026. The long-term objective is to integrate autonomous ride-hailing services into Dubai‘s public transport network, supporting the city’s broader ambitions to enhance road safety, improve quality of life, and deliver more efficient and sustainable mobility options for residents and visitors.

Dr. James Peng, Founder and CEO of Pony.ai, stated, “Dubai‘s robust transport infrastructure, supportive policy environment, and public acceptance of emerging technologies give us confidence in promoting the large-scale adoption of autonomous driving technology. Building on our collaboration with local partners and regulators, we are committed to accelerating the deployment of our robotaxi services in Dubai and across the broader Middle East market.”

Pony.ai announced its partnership with Dubai‘s RTA in May, followed by a robotaxi reveal ceremony in July. The two parties are now jointly advancing the development and deployment of Level 4 autonomous mobility solutions in the region, supporting Dubai‘s goal of converting 25% of citywide trips to autonomous transport by 2030.

The year 2025 has marked a turning point for Pony.ai, as it began mass production and deployment of its seventh-generation autonomous driving system, which was unveiled in April. By August, Pony.ai’s fleet had expanded to over 500 vehicles, covering more than 2,000 square kilometers of operational zones across China’s four Tier-1 cities: Beijing, Shanghai, Guangzhou, and Shenzhen.

In line with its vision of “autonomous mobility everywhere”, Pony.ai continues to expand its global footprint. Just a week ago, the company announced its entry into Singapore through a collaboration with ComfortDelGro to deploy autonomous vehicles. Earlier in September, Pony.ai also partnered with Mowasalat “Karwa”, Qatar’s leading transport service provider, to introduce self-driving technology on Qatari roads.

Additionally, Pony.ai is working with global ride-hailing platform Uber to integrate its robotaxis into the Uber app, with initial deployments anticipated in the Middle East. The company is also conducting on-road tests in Luxembourg with Emile Weber and has launched 24/7 testing operations in Seoul’s Gangnam district.

HONG KONG, Sept. 26, 2025 /PRNewswire/ — Govee, a global leader in smart lighting innovation, today announced the launch of new additions to its line of star light projectors. In addition to the Govee Star Light Projector (Nebula) unveiled at IFA 2025, the series welcomes two new models: the Govee Galaxy Light Projector 2 Pro and the Govee Star Light Projector (Ocean Wave). These new offerings are designed to bring the beauty of the cosmos into any living space, whether you’re looking to enhance your  dreamy bedroom decor, find a unique way for relaxation, or simply immerse yourself in a stunning celestial display.

Take Your Home Lighting to Cosmic Heights with the Govee Galaxy Light Projector 2 Pro

The Govee Galaxy Light Projector 2 Pro allows users to revel in the breathtaking beauty of the cosmos from the comfort of home – no spacecraft required. It equips an upgraded 4MP HD lens paired with a glass laminated disc, plus 8K ultra-high-definition image quality, delivering 100% higher resolution than the previous generation. This ensures sharp, blur-free details of nebulas, the Milky Way, and more, even when projecting at long distances. Reaching 230 lux, it remains clear even in low-light settings, such as bedrooms with nightlights or desk lamps on. Users can enjoy vivid star projections anytime without compromising visibility, bringing the magic of the night sky into your home effortlessly.

With eight mesmerizing projection discs, offering over 20 preset cosmic lighting effects and two dynamic laser motion forms, the Govee Galaxy Light Projector 2 Pro provides an immersive, interstellar experience. It also includes built-in audio features, enabling users to synchronize the stars with white noise or their favorite music, creating a serene and cozy ambiance, perfect for a night of tranquil slumber or contemplative meditation.

The Govee Star Light Projector (Nebula)

The Govee Star Light Projector (Nebula) delivers a dynamic, customizable cosmic experience. Featuring 7-zone dynamic nebula effects paired with green laser stars that shine in Blink and Orbit modes. Thanks to its RGBW lamp beads, you can fully customize each zone’s color and flow rhythm, crafting one-of-a-kind starscapes tailored to your taste. With a 540 ft² projection area, it easily covers entire rooms’ ceilings and walls with stunning visuals. With over 50 preset scene modes, a built-in Bluetooth speaker for music, and flexible DIY options, it’s ideal for personalized atmospheres. Also, it offers a smart sleep mode with gradual dimming and 18 white noises to enhance rest.

Govee Star Light Projector (Ocean Wave)

The Govee Star Light Projector (Ocean Wave) turns any room into a serene underwater sanctuary, blending flowing water visuals and soothing sounds for an immersive, relaxing atmosphere. It uses a dual-layer textured lens to project rich, dynamic ocean waves, instantly wrapping spaces in a calming aquatic vibe. With a 540 ft² projection range, it easily fills entire rooms—ideal for boosting relaxation, enhancing meditation sessions, or adding a unique aesthetic to your space.

You can fully customize the aquatic experience too: adjust the water pattern’s sparseness, brightness, and flow speed, or pick from 40+ preset scenes to match your mood or activity. It also supports smart wellness features, including a Sleep Mode that gradually dims to ease rest and brightens gently for natural awakening, helping foster healthy sleep habits. For deeper immersion, pair the visual tranquility with 18 built-in white noise options or stream your favorite music via Bluetooth—creating a stress-relieving experience that soothes both sight and sound.

Smart and Seamless Integration

All three new projectors offer seamless smart control and ecosystem integration. With Matter compatibility, these new light projectors integrate effortlessly into any smart home ecosystem, including Alexa, Google Home, and Apple Home. Through the Govee Home App, users can enjoy deeper customization options, including a smart sleep mode, white noise functionality, and a timer feature, putting full control of their home ambiance at their fingertips.

Pricing and  Availability

Govee Galaxy Light Projector 2 Pro is available on Govee website and Amazon, retailing for $179.99.
Govee Star Light Projector (Nebula) is available on Govee website and Amazon, retailing for $99.99.
Govee Star Light Projector (Ocean Wave) is available on  Govee website and Amazon, retailing for $89.99.
For more details about the brand and other outdoor lighting solutions, please visit govee.com.

About Govee

Govee has been revolutionizing the smart living experience since 2017, with innovative, efficient, and hassle-free ambient lighting solutions for the entire home. From living spaces and gaming setups to outdoor areas and beyond, Govee smart lighting is not just visually stunning, but transforms everyday moments into personalized and engaging lighting experiences. Embracing the idea that “Life is Colorful,” Govee is committed to bringing vibrant ambient lighting to every corner of the home, to fostering connections with users on both practical and emotional levels, and to making everyday moments brighter and more enjoyable.

BEIJING, Sept. 26, 2025 /PRNewswire/ — Concord Medical Services Holdings Limited (“Concord Medical” or the “Company”) (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced its unaudited consolidated financial results for the six months ended June 30, 2025^[1].

2025 First Half Highlights

• Total net revenues were RMB200.6 million (US$28.0 million) in the first half of 2025, representing a 8.3% decrease from total net revenues of RMB218.8 million in the same period last year. Total net revenues included the net revenues from the hospital business of RMB153.0 million (US$21.4 million) and the net revenues from the network business of RMB47.6 million (US$6.6 million).
• Gross loss was RMB4.3 million (US$0.6 million) in the first half of 2025, compared to the gross loss of RMB41.6 million in the first half of 2024. The gross loss margin was 2.1% for the first half of 2025, compared to 19.0% for the same period last year.
• Net loss attributable to ordinary shareholders in the first half of 2025 was RMB27.1 million (US$3.8 million), compared to RMB172.3 million in the same period last year.
• Basic and diluted loss per share for Class A and Class B ordinary shares in the first half of 2025 were both RMB0.21 (US$0.03), compared to RMB1.31 in the same period last year.
• Adjusted EBITDA^[2] was negative RMB62.2 million (US$8.7 million) in the first half of 2025, compared to negative RMB148.0 million in the same period last year.

Dr. Jianyu Yang, Chairman and Chief Executive Officer of Concord Medical, commented, “The precision of proton therapy helps prevent long-term damage to critical functional areas—including the brain, heart, and rectum—while allowing clinicians to safely escalate radiation doses to target sites to improve efficacy in refractory cancers. With minimal impact on surrounding normal tissues, patients benefit from fewer side effects and faster recovery, making proton therapy an optimal treatment option in cases where balancing efficacy and safety is critical.

As the first proton therapy center in South mainland China to commence clinical operations, Guangzhou Concord Cancer Hospital has developed specialized treatment protocols for a range of malignancies. In patients with nasopharyngeal carcinoma, aged between 10 and 71, we observed significant tumor regression, with elderly patients experiencing only mild mucosal reactions. For central nervous system tumors, the hospital achieved successful functional preservation even in extensive irradiation fields such as whole-brain and whole-spine treatments. In pediatric care, as of June 30, the Company treated its youngest proton therapy patient, a child of just over one year old. Through advanced radiotherapy techniques and careful anesthetic management, the hospital was able to provide effective protection and treatment.

These results highlight the clinical value of proton therapy in improving outcomes for challenging cancers while preserving function in critical organs. Looking forward, the Company will remain committed to advancing proton therapy, enhancing public understanding of precision radiotherapy, strengthening patient confidence, and expanding patient access to internationally advanced diagnostic and therapeutic technologies, innovative medications, and patient-centered care.”

2025 First Half Financial Results

Net Revenues

Hospital Business

Net revenues from the hospital business were RMB153.0 million (US$21.4 million) in the first half of 2025, representing a 11.1% increase from net revenues of RMB137.8 million in the first half of 2024, mainly because of the commencement of proton therapy operations at Guangzhou Concord Cancer Hospital.

Network Business

Net revenues from the network business were RMB47.6 million (US$6.6 million), representing a 41.3% decrease from net revenues of RMB81.0 million in the first half of 2024, mainly because (1) demand for medical equipment and software decreased under the current macroeconomic environment, leading to delayed overall business demand, and (2) operating lease revenue decreased since this is no longer the Company’s main business and expired contracts were not renewed.

Cost of Revenues

Hospital Business

Cost of revenues of the hospital business in the first half of 2025 was RMB157.2 million (US$21.9 million), representing a 9.6% decrease from cost of revenues of RMB174.0 million in the first half of 2024, mainly because (1) efficiency of human resources improved as the Company implemented a strategy focused on enhancing operational efficiency and reducing costs, (2) consumables cost, maintenance cost and lease cost decreased along with the development of the hospital business.

Network Business

Cost of revenues of the network business was RMB47.7million (US$6.7 million), representing a 44.8% decrease from RMB86.4 million in the first half of 2024, mainly because of the decrease in cost as a result of the decrease in revenue generated from sales and installation of medical equipment and software, and from management and technical support services.

Gross Loss and Gross Loss Margin

Gross loss from the operating business was RMB4.3million (US$0.6 million) in the first half of 2025, compared to RMB41.6 million in the same period last year. The gross loss margin for the first half of 2025 was 2.1%, compared to the gross loss margin of 19.0% for the same period last year. The improvement in gross loss margin of the operating business was mainly because of adjustments in the Company’s revenue structure, with the commencement of the proton therapy business bringing efficiency improvements, and the strategic focus on enhancing operational efficiency and reducing costs.

Operating Expenses

Selling expenses were RMB21.0 million (US$2.9 million) in the first half of 2025, compared to RMB25.0 million in the first half of 2024. Selling expenses as a percentage of net revenues was 10.5% in the first half of 2025, compared to 11.4% in the first half of 2024.

General and administrative expenses were RMB119.4 million (US$16.7 million) in the first half of 2025, of which employee benefit expenses were RMB51.0 million (US$7.1 million). In the same period of last year, general and administrative expenses were RMB131.2 million. The decrease was mainly attributable to the decrease in staff cost and listing expenses, and the strategic focus on enhancing operational efficiency and reducing costs. General and administrative expenses as a percentage of net revenues were 59.5% in the first half of 2025, compared to 59.9% in the first half of 2024.

Capital Expenditures

Comparing to RMB168.4 million in the first half of 2024, capital expenditures were RMB100.6 million (US$14.0 million) in the first half of 2025, mainly due to the decrease in deposit for equipment and construction fees for our hospital business.

Bank Loans and Other Borrowings

As of June 30, 2025, the Company had bank loans and other borrowings totaling RMB3.6 billion (US$508.4 million).

About Non-GAAP Financial Measures

To supplement the consolidated financial statements presented in accordance with United States Generally Accepted Accounting Principles (“GAAP”), Concord Medical uses certain non-GAAP measures. Concord Medical presents the non-GAAP measure of adjusted EBITDA, which is defined in this announcement as net loss plus interest expenses, net, income tax expenses, depreciation and amortization and other adjustments. Other adjustments include foreign exchange loss, net, other income, net, gain on disposal of equity method investment, gain on disposal of subsidiaries, change in fair value of derivative liability, changes in fair value of short-term investments and gain on disposal of long-lived equipment. Furthermore, adjusted EBITDA eliminates the impact of items that the Company does not consider to be indicative of the performance of the network business and hospital business. The Company believes investors will similarly use adjusted EBITDA as one of the key metrics to evaluate its financial performance and to compare its current operating results with corresponding historical periods and with other companies in the healthcare services industry. The presentation of these additional measures should not be considered a substitute for or superior to GAAP results or as being comparable to results reported or forecasted by other companies. The non-GAAP measures have been reconciled to GAAP measures in the attached financial information.

About Concord Medical

Concord Medical Services Holdings Limited is a healthcare provider featuring a full cycle of premium oncology services including cancer diagnosis, treatment, education and prevention. The Company focuses on providing multidisciplinary cancer care in all aspects of oncology healthcare services in its cancer hospitals and equipping them with technologically advanced equipment such as the state-of-the-art proton therapy system. The Company is striving to improve the quality and accessibility of cancer care through its network of self-owned cancer hospitals and clinics as well as partnered hospitals across China. For more information, please see http://ir.ccm.cn. 

Safe Harbor Statement

This announcement contains forward-looking statements. These forward-looking statements can be identified by words or phrases such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar expressions. Forward-looking statements are inherently subject to uncertainties and contingencies beyond the Company’s control and based upon premises with respect to future business decisions, which are subject to change. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. The Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.